MAIA Biotechnology, Inc. (MAIA)
USD 1.94
(-11.82%)
USD 1.94
(-11.82%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.18 Million USD | -24.77% |
| 2022 | -16.17 Million USD | -107.74% |
| 2021 | -7.78 Million USD | -11.63% |
| 2020 | -6.97 Million USD | -0.78% |
| 2019 | -6.92 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.83 Million USD | 3.84% |
| 2024 Q1 | -3.96 Million USD | 38.06% |
| 2023 Q1 | -4.18 Million USD | 20.97% |
| 2023 FY | -20.35 Million USD | -25.86% |
| 2023 Q3 | -4.95 Million USD | -6.24% |
| 2023 Q4 | -6.4 Million USD | -29.25% |
| 2023 Q2 | -4.66 Million USD | -11.48% |
| 2022 Q2 | -3.44 Million USD | 0.04% |
| 2022 Q1 | -3.44 Million USD | -14.81% |
| 2022 FY | -16.17 Million USD | -107.74% |
| 2022 Q4 | -5.29 Million USD | -32.48% |
| 2022 Q3 | -3.99 Million USD | -16.1% |
| 2021 Q2 | -1.5 Million USD | -43.07% |
| 2021 FY | -7.78 Million USD | -11.63% |
| 2021 Q1 | -1.05 Million USD | 68.58% |
| 2021 Q4 | -2.99 Million USD | -34.31% |
| 2021 Q3 | -2.23 Million USD | -48.56% |
| 2020 Q4 | -3.34 Million USD | -307.55% |
| 2020 Q3 | -820.53 Thousand USD | 0.0% |
| 2020 FY | -6.97 Million USD | -0.78% |
| 2019 FY | -6.92 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 36.764% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -112.044% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 50.642% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 61.128% |
| Azitra, Inc. | -7.61 Million USD | -164.986% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -146.277% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -194.106% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 30.386% |
| CEL-SCI Corporation | -31.47 Million USD | 35.88% |
| iBio, Inc. | -16.63 Million USD | -21.332% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 18.399% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 15.079% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -43.638% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -303.406% |
| NanoViricides, Inc. | -8.51 Million USD | -136.991% |
| Oragenics, Inc. | -20.9 Million USD | 3.456% |
| BiomX Inc. | -27.68 Million USD | 27.1% |
| BiomX Inc. | -27.68 Million USD | 27.1% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 292.948% |
| Palatin Technologies, Inc. | -22.49 Million USD | 10.285% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 51.983% |